Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections - A Look At Korea (Part 3)
This article was originally published in PharmAsia News
Executive Summary
South Korea's pharmaceutical regulatory program is in a state of change, and the Korea FDA is open to ongoing changes to support regulatory harmonization with the rest of the world. That openness presents an opportunity for industry to influence some differences between Korea and the rest of the world, according to said Jeffrey Ferguson, Eli Lilly's director of global regulatory affairs CMC
You may also be interested in...
India Lags China In Regional GMP Harmonization – ISPE Singapore
China is actively seeking to enter a global agreement on good manufacturing processes for drugs while India remains aloof from a growing Asia movement on harmonization for inspections, training and rules in the industry.
Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections: A Look At India (Part 6)
Like most other Asian nations, India will not consider an application for marketing approval of a drug unless it comes with a certificate of pharmaceutical product showing that a major market has already approved the product, said Mark Rosolowsky, executive director, GRS-CMC, Bristol-Myers Squibb
Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections: A Look At India (Part 6)
Like most other Asian nations, India will not consider an application for marketing approval of a drug unless it comes with a certificate of pharmaceutical product showing that a major market has already approved the product, said Mark Rosolowsky, executive director, GRS-CMC, Bristol-Myers Squibb